ATE459646T1 - Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist - Google Patents

Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist

Info

Publication number
ATE459646T1
ATE459646T1 AT02775586T AT02775586T ATE459646T1 AT E459646 T1 ATE459646 T1 AT E459646T1 AT 02775586 T AT02775586 T AT 02775586T AT 02775586 T AT02775586 T AT 02775586T AT E459646 T1 ATE459646 T1 AT E459646T1
Authority
AT
Austria
Prior art keywords
deletion
exon
detection
diagnostic method
csf
Prior art date
Application number
AT02775586T
Other languages
English (en)
Inventor
Sang-Yup Lee
Ki-Jun Jeong
Hyun-Cheol Chung
Nae-Choon Yoo
Ki-Chang Keum
Won-Min Yoo
Original Assignee
Medigenes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medigenes filed Critical Medigenes
Application granted granted Critical
Publication of ATE459646T1 publication Critical patent/ATE459646T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
AT02775586T 2001-09-28 2002-09-28 Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist ATE459646T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20010060826 2001-09-28
PCT/KR2002/001825 WO2003027288A1 (en) 2001-09-28 2002-09-28 Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3

Publications (1)

Publication Number Publication Date
ATE459646T1 true ATE459646T1 (de) 2010-03-15

Family

ID=19714831

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02775586T ATE459646T1 (de) 2001-09-28 2002-09-28 Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist

Country Status (9)

Country Link
US (10) US20040247562A1 (de)
EP (1) EP1446485B1 (de)
JP (1) JP4413611B2 (de)
KR (2) KR100523328B1 (de)
CN (1) CN100491527C (de)
AT (1) ATE459646T1 (de)
AU (1) AU2002343900B2 (de)
DE (1) DE60235568D1 (de)
WO (1) WO2003027288A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1828241A1 (de) 2004-12-23 2007-09-05 Laboratoires Serono S.A. G-csf polypeptide und deren verwendungen
KR20070019524A (ko) * 2005-08-12 2007-02-15 메디제네스(주) 암 진단 마커 및 방법
US7909983B2 (en) * 2006-05-04 2011-03-22 Nipro Diagnostics, Inc. System and methods for automatically recognizing a control solution
NZ602255A (en) 2010-03-04 2014-04-30 Pfenex Inc Method for producing soluble recombinant interferon protein without denaturing
CA2794740C (en) 2010-04-01 2019-12-31 Pfenex Inc. Methods for g-csf production in a pseudomonas host cell

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6004548A (en) * 1985-08-23 1999-12-21 Amgen, Inc. Analogs of pluripotent granulocyte colony-stimulating factor
DE4014750A1 (de) * 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
US5581476A (en) * 1993-01-28 1996-12-03 Amgen Inc. Computer-based methods and articles of manufacture for preparing G-CSF analogs
WO1995023862A1 (en) * 1994-03-04 1995-09-08 Ludwig Institute For Cancer Research Animals with targeted gene disruption
US6303301B1 (en) * 1997-01-13 2001-10-16 Affymetrix, Inc. Expression monitoring for gene function identification
CN1061992C (zh) * 1997-11-19 2001-02-14 蒋永平 新的重组人粒细胞集落刺激因子及其药物组合物
KR100365482B1 (ko) 1999-12-28 2002-12-26 철 근 김 종양 억제 유전자의 프라이머쌍을 포함하는 암 진단용 벡터

Also Published As

Publication number Publication date
WO2003027288A1 (en) 2003-04-03
CN100491527C (zh) 2009-05-27
AU2002343900B2 (en) 2007-04-26
KR20050098821A (ko) 2005-10-12
US20120329078A1 (en) 2012-12-27
EP1446485A4 (de) 2005-05-25
US20050158810A1 (en) 2005-07-21
KR100523328B1 (ko) 2005-10-24
US20050170417A1 (en) 2005-08-04
US20140005365A1 (en) 2014-01-02
US20050170416A1 (en) 2005-08-04
JP2005503810A (ja) 2005-02-10
KR20030027870A (ko) 2003-04-07
US20120322684A1 (en) 2012-12-20
JP4413611B2 (ja) 2010-02-10
CN1561395A (zh) 2005-01-05
US20050244856A1 (en) 2005-11-03
DE60235568D1 (de) 2010-04-15
WO2003027288A9 (en) 2003-06-05
EP1446485B1 (de) 2010-03-03
EP1446485A1 (de) 2004-08-18
US20050266430A1 (en) 2005-12-01
KR100716014B1 (ko) 2007-05-08
US20100286381A1 (en) 2010-11-11
US8324363B2 (en) 2012-12-04
US20040247562A1 (en) 2004-12-09

Similar Documents

Publication Publication Date Title
Méndez et al. Transcriptional expression profiles of oral squamous cell carcinomas
Baba et al. A novel allelic variant of serum amyloic A, SAA1γ: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA–amyloidosis
AU722819B2 (en) Diagnosis of disease state using mRNA profiles
TWI540321B (zh) 檢測膀胱癌之尿液標記物
DE69521813D1 (de) Verfahrens und testsätze zur diagnose periodentahlkrankheiten und zur vorhersage des risikos der progression davon
DE69518558D1 (de) Verfahren zur Diagnose von Krebs oder Präkanzerose durch Nachweis IRF-1-spezifischer RNS
BR112021003095A2 (pt) métodos relacionados à gravidade e progressão de lesão pré-maligna bronquial
DE60239089D1 (de) Verfahren zur Diagnose von Krebserkrankungen durch Messung der TIMP-1-Glycosylationsveränderungen im Zusammenhang mit der Tumorgenese und Metastasen
DK0757723T3 (da) Genetiske ændringer, der korrelerer med lungecarcinoma
ATE332979T1 (de) Detektion von änderungen von tumor-suppressor genen zur diagnose von krebs
ATE459646T1 (de) Diagnoseverfahren für krebs, das durch den nachweis der deletion des g-csf-exons 3 gekennzeichnet ist
ATE419533T1 (de) Verfahren/präparat zur erkennung von pankreaskrebs
DE69226775D1 (de) Dns-sequenzen von hpv42 papillomavirus :verwendungsmöglichkeit für diagnose
DE60334408D1 (de) Nsäuren
ATE440138T1 (de) Mutationen des parkin-gens, zusammensetzungen, verfahren und verwendungen
Smith et al. Dominant toxin hypothesis: Unravelling the venom phenotype across micro and macroevolution
EA200600012A1 (ru) Полиморфизм человеческого гена nbs1, полезный для диагностики наследственной предрасположенности к раку
ES2700790T3 (es) Marcador epigenético para la identificación de linfocitos T il17 positivos en muestras complejas
DE602004024300D1 (de) Anti-BAMBI Antikörper oder RNA zur Diagnose und Therapie bei Dickdarm- oder Leberkrebs
KR102928508B1 (ko) 대장암 재발 예측용 바이오 마커
KR102893524B1 (ko) 간질환 환자에서 간 섬유화 진행의 예후를 예측하기 위한 분석방법
Caetano et al. Mapping the Spatial Dynamics of the Human Oral Mucosa in Chronic Inflammatory Disease
ATE369426T1 (de) Nukleinsäure- und aminosäuresequenzen von durch hämoglobin induzierbaren genen aus candida albicans und die verwendung dieser sequenzen in reagenzien zur diagnose von disseminierten candida albicans infektionen
JP6964358B2 (ja) ヒトにおける骨髄腫瘍の発症又は発症リスクを検査する指標の取得方法、ヒトにおけるｄｄｘ４１遺伝子の体細胞変異の存在又は将来的な発生を予測する指標の取得方法、並びに、これらの検査又は予測のためのキット
WO2003062398A3 (en) NEW TUMOR SUPPRESSOR GENE, p28ING5

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties